114 related articles for article (PubMed ID: 21839068)
41. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.
Ellinger J; Wittkamp V; Albers P; Perabo FG; Mueller SC; von Ruecker A; Bastian PJ
J Urol; 2009 Jan; 181(1):363-71. PubMed ID: 19010497
[TBL] [Abstract][Full Text] [Related]
42. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
[TBL] [Abstract][Full Text] [Related]
43. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
44. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma.
Herbst RA; Larson A; Weiss J; Cavenee WK; Hampton GM; Arden KC
Cancer Res; 1995 Jun; 55(12):2494-6. PubMed ID: 7780954
[TBL] [Abstract][Full Text] [Related]
45. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients.
Ponti G; Maccaferri M; Manfredini M; Kaleci S; Mandrioli M; Pellacani G; Ozben T; Depenni R; Bianchi G; Pirola GM; Tomasi A
Clin Chim Acta; 2018 Apr; 479():14-19. PubMed ID: 29309771
[TBL] [Abstract][Full Text] [Related]
46. Circulating biomarkers in malignant melanoma.
Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
[TBL] [Abstract][Full Text] [Related]
47. Features of Circulating DNA Fragmentation in Blood of Healthy Females and Breast Cancer Patients.
Tamkovich SN; Kirushina NA; Voytsitskiy VE; Tkachuk VA; Laktionov PP
Adv Exp Med Biol; 2016; 924():47-51. PubMed ID: 27753018
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma.
Mauger F; Dulary C; Daviaud C; Deleuze JF; Tost J
Anal Bioanal Chem; 2015 Sep; 407(22):6873-8. PubMed ID: 26123439
[TBL] [Abstract][Full Text] [Related]
49. Circulating cell-free DNA in cancer.
Pinzani P; Salvianti F; Orlando C; Pazzagli M
Methods Mol Biol; 2014; 1160():133-45. PubMed ID: 24740228
[TBL] [Abstract][Full Text] [Related]
50. [In vivo analysis of circulating cell-free DNA release and degradation].
Barták BK; Nagy ZB; Spisák S; Tulassay Z; Dank M; Igaz P; Molnár B
Orv Hetil; 2018 Feb; 159(6):223-233. PubMed ID: 29400102
[TBL] [Abstract][Full Text] [Related]
51. Lack of association between EGF 61A>G polymorphism and plasma EGF concentration in the STANISLAS family study.
Berrahmoune H; Herbeth B; Lamont JV; Masson C; FitzGerald SP; Visvikis-Siest S
J Invest Dermatol; 2007 Apr; 127(4):969-70. PubMed ID: 17170735
[No Abstract] [Full Text] [Related]
52. Protease Activity and Cell-Free DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients.
Tamkovich S; Bryzgunova O
J Immunoassay Immunochem; 2016; 37(2):141-53. PubMed ID: 26264080
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in clinical applications of circulating cell-free DNA integrity.
Yu J; Gu G; Ju S
Lab Med; 2014; 45(1):6-11. PubMed ID: 24719978
[TBL] [Abstract][Full Text] [Related]
54. Letter to the Editor regarding proteomic strategies and biomarker identification in melanoma.
Phelps A; Murphy MJ
Clin Biochem; 2013 Sep; 46(13-14):1309. PubMed ID: 23810584
[No Abstract] [Full Text] [Related]
55. Plasma RNA integrity analysis: methodology and validation.
Wong BC; Lo YM
Ann N Y Acad Sci; 2006 Sep; 1075():174-8. PubMed ID: 17108208
[TBL] [Abstract][Full Text] [Related]
56. Fragmentation patterns of circulating cell-free DNA demonstrate biomarker potential for human cancers.
Zhang Z; Zhang W
Biotarget; 2019 Aug; 3():. PubMed ID: 31468030
[No Abstract] [Full Text] [Related]
57. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
Lipson EJ; Velculescu VE; Pritchard TS; Sausen M; Pardoll DM; Topalian SL; Diaz LA
J Immunother Cancer; 2014; 2(1):42. PubMed ID: 25516806
[TBL] [Abstract][Full Text] [Related]
58. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
[TBL] [Abstract][Full Text] [Related]
59. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Newman AM; Bratman SV; To J; Wynne JF; Eclov NC; Modlin LA; Liu CL; Neal JW; Wakelee HA; Merritt RE; Shrager JB; Loo BW; Alizadeh AA; Diehn M
Nat Med; 2014 May; 20(5):548-54. PubMed ID: 24705333
[TBL] [Abstract][Full Text] [Related]
60. Circulating tumor-derived DNA is shorter than somatic DNA in plasma.
Mouliere F; Rosenfeld N
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3178-9. PubMed ID: 25733911
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
